Pharma & Healthcare
Targeted Drugs for Colorectal Cancer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Oct 12, 24
- ID: 163495
- Pages: 130
- Figures: 248
- Views: 12
Targeted therapy is to design corresponding therapeutic drugs for the identified cancer-causing site (the site can be a protein molecule inside the tumor cell or a gene fragment) at the cellular molecular level, and the drug enters the body It will specifically select oncogenic sites to combine and act, so that tumor cells will die specifically, without affecting normal tissue cells around the tumor.
The global market for Targeted Drugs for Colorectal Cancer was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Colorectal Cancer, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Targeted Drugs for Colorectal Cancer by region & country, by Type, and by Application.
The Targeted Drugs for Colorectal Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Colorectal Cancer.
Market Segmentation
By Company
Merck
Amgen
F. Hoffmann-La Roche Ltd
Novartis
Array BioPharma
Genentech
Bayer
Sanofi
Lilly
Bristol myers squibb
MSD lreland
HUTCHMED
Segment by Type:
EGFR Target
BRAF Target
MEK1/2 Targets
BRAF V600 Target
HER2 Target
VEGFR-1/2/3 Targets
PD-1 Target
CTLA-4 Target
Segment by Application
Hospital
Specialty Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Targeted Drugs for Colorectal Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Targeted Drugs for Colorectal Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Targeted Drugs for Colorectal Cancer in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Targeted Drugs for Colorectal Cancer was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Colorectal Cancer, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Targeted Drugs for Colorectal Cancer by region & country, by Type, and by Application.
The Targeted Drugs for Colorectal Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Colorectal Cancer.
Market Segmentation
By Company
Merck
Amgen
F. Hoffmann-La Roche Ltd
Novartis
Array BioPharma
Genentech
Bayer
Sanofi
Lilly
Bristol myers squibb
MSD lreland
HUTCHMED
Segment by Type:
EGFR Target
BRAF Target
MEK1/2 Targets
BRAF V600 Target
HER2 Target
VEGFR-1/2/3 Targets
PD-1 Target
CTLA-4 Target
Segment by Application
Hospital
Specialty Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Targeted Drugs for Colorectal Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Targeted Drugs for Colorectal Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Targeted Drugs for Colorectal Cancer in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Targeted Drugs for Colorectal Cancer Product Introduction
1.2 Global Targeted Drugs for Colorectal Cancer Market Size Forecast
1.2.1 Global Targeted Drugs for Colorectal Cancer Sales Value (2019-2030)
1.2.2 Global Targeted Drugs for Colorectal Cancer Sales Volume (2019-2030)
1.2.3 Global Targeted Drugs for Colorectal Cancer Sales Price (2019-2030)
1.3 Targeted Drugs for Colorectal Cancer Market Trends & Drivers
1.3.1 Targeted Drugs for Colorectal Cancer Industry Trends
1.3.2 Targeted Drugs for Colorectal Cancer Market Drivers & Opportunity
1.3.3 Targeted Drugs for Colorectal Cancer Market Challenges
1.3.4 Targeted Drugs for Colorectal Cancer Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Targeted Drugs for Colorectal Cancer Players Revenue Ranking (2023)
2.2 Global Targeted Drugs for Colorectal Cancer Revenue by Company (2019-2024)
2.3 Global Targeted Drugs for Colorectal Cancer Players Sales Volume Ranking (2023)
2.4 Global Targeted Drugs for Colorectal Cancer Sales Volume by Company Players (2019-2024)
2.5 Global Targeted Drugs for Colorectal Cancer Average Price by Company (2019-2024)
2.6 Key Manufacturers Targeted Drugs for Colorectal Cancer Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Targeted Drugs for Colorectal Cancer Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Targeted Drugs for Colorectal Cancer
2.9 Targeted Drugs for Colorectal Cancer Market Competitive Analysis
2.9.1 Targeted Drugs for Colorectal Cancer Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Targeted Drugs for Colorectal Cancer Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Colorectal Cancer as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 EGFR Target
3.1.2 BRAF Target
3.1.3 MEK1/2 Targets
3.1.4 BRAF V600 Target
3.1.5 HER2 Target
3.1.6 VEGFR-1/2/3 Targets
3.1.7 PD-1 Target
3.1.8 CTLA-4 Target
3.2 Global Targeted Drugs for Colorectal Cancer Sales Value by Type
3.2.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Targeted Drugs for Colorectal Cancer Sales Value, by Type (2019-2030)
3.2.3 Global Targeted Drugs for Colorectal Cancer Sales Value, by Type (%) (2019-2030)
3.3 Global Targeted Drugs for Colorectal Cancer Sales Volume by Type
3.3.1 Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Type (2019-2030)
3.3.3 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Type (%) (2019-2030)
3.4 Global Targeted Drugs for Colorectal Cancer Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Specialty Clinic
4.2 Global Targeted Drugs for Colorectal Cancer Sales Value by Application
4.2.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Targeted Drugs for Colorectal Cancer Sales Value, by Application (2019-2030)
4.2.3 Global Targeted Drugs for Colorectal Cancer Sales Value, by Application (%) (2019-2030)
4.3 Global Targeted Drugs for Colorectal Cancer Sales Volume by Application
4.3.1 Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Application (2019-2030)
4.3.3 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Application (%) (2019-2030)
4.4 Global Targeted Drugs for Colorectal Cancer Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Region
5.1.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2019-2024)
5.1.3 Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2025-2030)
5.1.4 Global Targeted Drugs for Colorectal Cancer Sales Value by Region (%), (2019-2030)
5.2 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region
5.2.1 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2019-2024)
5.2.3 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2025-2030)
5.2.4 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (%), (2019-2030)
5.3 Global Targeted Drugs for Colorectal Cancer Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.4.2 North America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.5.2 Europe Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.6.2 Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.7.2 South America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.8.2 Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value
6.2.1 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.2.2 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.3.2 United States Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.4.2 Europe Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.5.2 China Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.5.3 China Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.6.2 Japan Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.7.2 South Korea Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.8.2 Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.9.2 India Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.9.3 India Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Targeted Drugs for Colorectal Cancer Product Offerings
7.1.5 Merck Recent Development
7.2 Amgen
7.2.1 Amgen Company Information
7.2.2 Amgen Introduction and Business Overview
7.2.3 Amgen Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Amgen Targeted Drugs for Colorectal Cancer Product Offerings
7.2.5 Amgen Recent Development
7.3 F. Hoffmann-La Roche Ltd
7.3.1 F. Hoffmann-La Roche Ltd Company Information
7.3.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
7.3.3 F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.3.4 F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Product Offerings
7.3.5 F. Hoffmann-La Roche Ltd Recent Development
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Introduction and Business Overview
7.4.3 Novartis Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Novartis Targeted Drugs for Colorectal Cancer Product Offerings
7.4.5 Novartis Recent Development
7.5 Array BioPharma
7.5.1 Array BioPharma Company Information
7.5.2 Array BioPharma Introduction and Business Overview
7.5.3 Array BioPharma Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Array BioPharma Targeted Drugs for Colorectal Cancer Product Offerings
7.5.5 Array BioPharma Recent Development
7.6 Genentech
7.6.1 Genentech Company Information
7.6.2 Genentech Introduction and Business Overview
7.6.3 Genentech Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Genentech Targeted Drugs for Colorectal Cancer Product Offerings
7.6.5 Genentech Recent Development
7.7 Bayer
7.7.1 Bayer Company Information
7.7.2 Bayer Introduction and Business Overview
7.7.3 Bayer Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Bayer Targeted Drugs for Colorectal Cancer Product Offerings
7.7.5 Bayer Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sanofi Targeted Drugs for Colorectal Cancer Product Offerings
7.8.5 Sanofi Recent Development
7.9 Lilly
7.9.1 Lilly Company Information
7.9.2 Lilly Introduction and Business Overview
7.9.3 Lilly Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Lilly Targeted Drugs for Colorectal Cancer Product Offerings
7.9.5 Lilly Recent Development
7.10 Bristol myers squibb
7.10.1 Bristol myers squibb Company Information
7.10.2 Bristol myers squibb Introduction and Business Overview
7.10.3 Bristol myers squibb Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Bristol myers squibb Targeted Drugs for Colorectal Cancer Product Offerings
7.10.5 Bristol myers squibb Recent Development
7.11 MSD lreland
7.11.1 MSD lreland Company Information
7.11.2 MSD lreland Introduction and Business Overview
7.11.3 MSD lreland Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.11.4 MSD lreland Targeted Drugs for Colorectal Cancer Product Offerings
7.11.5 MSD lreland Recent Development
7.12 HUTCHMED
7.12.1 HUTCHMED Company Information
7.12.2 HUTCHMED Introduction and Business Overview
7.12.3 HUTCHMED Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.12.4 HUTCHMED Targeted Drugs for Colorectal Cancer Product Offerings
7.12.5 HUTCHMED Recent Development
8 Industry Chain Analysis
8.1 Targeted Drugs for Colorectal Cancer Industrial Chain
8.2 Targeted Drugs for Colorectal Cancer Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Targeted Drugs for Colorectal Cancer Sales Model
8.5.2 Sales Channel
8.5.3 Targeted Drugs for Colorectal Cancer Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Targeted Drugs for Colorectal Cancer Product Introduction
1.2 Global Targeted Drugs for Colorectal Cancer Market Size Forecast
1.2.1 Global Targeted Drugs for Colorectal Cancer Sales Value (2019-2030)
1.2.2 Global Targeted Drugs for Colorectal Cancer Sales Volume (2019-2030)
1.2.3 Global Targeted Drugs for Colorectal Cancer Sales Price (2019-2030)
1.3 Targeted Drugs for Colorectal Cancer Market Trends & Drivers
1.3.1 Targeted Drugs for Colorectal Cancer Industry Trends
1.3.2 Targeted Drugs for Colorectal Cancer Market Drivers & Opportunity
1.3.3 Targeted Drugs for Colorectal Cancer Market Challenges
1.3.4 Targeted Drugs for Colorectal Cancer Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Targeted Drugs for Colorectal Cancer Players Revenue Ranking (2023)
2.2 Global Targeted Drugs for Colorectal Cancer Revenue by Company (2019-2024)
2.3 Global Targeted Drugs for Colorectal Cancer Players Sales Volume Ranking (2023)
2.4 Global Targeted Drugs for Colorectal Cancer Sales Volume by Company Players (2019-2024)
2.5 Global Targeted Drugs for Colorectal Cancer Average Price by Company (2019-2024)
2.6 Key Manufacturers Targeted Drugs for Colorectal Cancer Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Targeted Drugs for Colorectal Cancer Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Targeted Drugs for Colorectal Cancer
2.9 Targeted Drugs for Colorectal Cancer Market Competitive Analysis
2.9.1 Targeted Drugs for Colorectal Cancer Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Targeted Drugs for Colorectal Cancer Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Colorectal Cancer as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 EGFR Target
3.1.2 BRAF Target
3.1.3 MEK1/2 Targets
3.1.4 BRAF V600 Target
3.1.5 HER2 Target
3.1.6 VEGFR-1/2/3 Targets
3.1.7 PD-1 Target
3.1.8 CTLA-4 Target
3.2 Global Targeted Drugs for Colorectal Cancer Sales Value by Type
3.2.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Targeted Drugs for Colorectal Cancer Sales Value, by Type (2019-2030)
3.2.3 Global Targeted Drugs for Colorectal Cancer Sales Value, by Type (%) (2019-2030)
3.3 Global Targeted Drugs for Colorectal Cancer Sales Volume by Type
3.3.1 Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Type (2019-2030)
3.3.3 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Type (%) (2019-2030)
3.4 Global Targeted Drugs for Colorectal Cancer Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Specialty Clinic
4.2 Global Targeted Drugs for Colorectal Cancer Sales Value by Application
4.2.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Targeted Drugs for Colorectal Cancer Sales Value, by Application (2019-2030)
4.2.3 Global Targeted Drugs for Colorectal Cancer Sales Value, by Application (%) (2019-2030)
4.3 Global Targeted Drugs for Colorectal Cancer Sales Volume by Application
4.3.1 Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Application (2019-2030)
4.3.3 Global Targeted Drugs for Colorectal Cancer Sales Volume, by Application (%) (2019-2030)
4.4 Global Targeted Drugs for Colorectal Cancer Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Region
5.1.1 Global Targeted Drugs for Colorectal Cancer Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2019-2024)
5.1.3 Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2025-2030)
5.1.4 Global Targeted Drugs for Colorectal Cancer Sales Value by Region (%), (2019-2030)
5.2 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region
5.2.1 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2019-2024)
5.2.3 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2025-2030)
5.2.4 Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (%), (2019-2030)
5.3 Global Targeted Drugs for Colorectal Cancer Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.4.2 North America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.5.2 Europe Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.6.2 Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.7.2 South America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
5.8.2 Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value
6.2.1 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.2.2 Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.3.2 United States Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.4.2 Europe Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.5.2 China Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.5.3 China Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.6.2 Japan Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.7.2 South Korea Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.8.2 Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Targeted Drugs for Colorectal Cancer Sales Value, 2019-2030
6.9.2 India Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
6.9.3 India Targeted Drugs for Colorectal Cancer Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Targeted Drugs for Colorectal Cancer Product Offerings
7.1.5 Merck Recent Development
7.2 Amgen
7.2.1 Amgen Company Information
7.2.2 Amgen Introduction and Business Overview
7.2.3 Amgen Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Amgen Targeted Drugs for Colorectal Cancer Product Offerings
7.2.5 Amgen Recent Development
7.3 F. Hoffmann-La Roche Ltd
7.3.1 F. Hoffmann-La Roche Ltd Company Information
7.3.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
7.3.3 F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.3.4 F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Product Offerings
7.3.5 F. Hoffmann-La Roche Ltd Recent Development
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Introduction and Business Overview
7.4.3 Novartis Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Novartis Targeted Drugs for Colorectal Cancer Product Offerings
7.4.5 Novartis Recent Development
7.5 Array BioPharma
7.5.1 Array BioPharma Company Information
7.5.2 Array BioPharma Introduction and Business Overview
7.5.3 Array BioPharma Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Array BioPharma Targeted Drugs for Colorectal Cancer Product Offerings
7.5.5 Array BioPharma Recent Development
7.6 Genentech
7.6.1 Genentech Company Information
7.6.2 Genentech Introduction and Business Overview
7.6.3 Genentech Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Genentech Targeted Drugs for Colorectal Cancer Product Offerings
7.6.5 Genentech Recent Development
7.7 Bayer
7.7.1 Bayer Company Information
7.7.2 Bayer Introduction and Business Overview
7.7.3 Bayer Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Bayer Targeted Drugs for Colorectal Cancer Product Offerings
7.7.5 Bayer Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sanofi Targeted Drugs for Colorectal Cancer Product Offerings
7.8.5 Sanofi Recent Development
7.9 Lilly
7.9.1 Lilly Company Information
7.9.2 Lilly Introduction and Business Overview
7.9.3 Lilly Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Lilly Targeted Drugs for Colorectal Cancer Product Offerings
7.9.5 Lilly Recent Development
7.10 Bristol myers squibb
7.10.1 Bristol myers squibb Company Information
7.10.2 Bristol myers squibb Introduction and Business Overview
7.10.3 Bristol myers squibb Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Bristol myers squibb Targeted Drugs for Colorectal Cancer Product Offerings
7.10.5 Bristol myers squibb Recent Development
7.11 MSD lreland
7.11.1 MSD lreland Company Information
7.11.2 MSD lreland Introduction and Business Overview
7.11.3 MSD lreland Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.11.4 MSD lreland Targeted Drugs for Colorectal Cancer Product Offerings
7.11.5 MSD lreland Recent Development
7.12 HUTCHMED
7.12.1 HUTCHMED Company Information
7.12.2 HUTCHMED Introduction and Business Overview
7.12.3 HUTCHMED Targeted Drugs for Colorectal Cancer Sales, Revenue and Gross Margin (2019-2024)
7.12.4 HUTCHMED Targeted Drugs for Colorectal Cancer Product Offerings
7.12.5 HUTCHMED Recent Development
8 Industry Chain Analysis
8.1 Targeted Drugs for Colorectal Cancer Industrial Chain
8.2 Targeted Drugs for Colorectal Cancer Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Targeted Drugs for Colorectal Cancer Sales Model
8.5.2 Sales Channel
8.5.3 Targeted Drugs for Colorectal Cancer Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Targeted Drugs for Colorectal Cancer Market Trends
Table 2. Targeted Drugs for Colorectal Cancer Market Drivers & Opportunity
Table 3. Targeted Drugs for Colorectal Cancer Market Challenges
Table 4. Targeted Drugs for Colorectal Cancer Market Restraints
Table 5. Global Targeted Drugs for Colorectal Cancer Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Company (2019-2024)
Table 7. Global Targeted Drugs for Colorectal Cancer Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Targeted Drugs for Colorectal Cancer Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Targeted Drugs for Colorectal Cancer Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Targeted Drugs for Colorectal Cancer Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Targeted Drugs for Colorectal Cancer Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Targeted Drugs for Colorectal Cancer
Table 13. Global Targeted Drugs for Colorectal Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Colorectal Cancer as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Targeted Drugs for Colorectal Cancer Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Targeted Drugs for Colorectal Cancer Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Targeted Drugs for Colorectal Cancer Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Targeted Drugs for Colorectal Cancer Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Targeted Drugs for Colorectal Cancer Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Targeted Drugs for Colorectal Cancer Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Targeted Drugs for Colorectal Cancer Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2019-2024) & (%)
Table 44. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2025-2030) & (%)
Table 45. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2019-2024) & (%)
Table 49. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2025-2030) & (%)
Table 50. Global Targeted Drugs for Colorectal Cancer Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Targeted Drugs for Colorectal Cancer Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume, (2025-2030) & (K Units)
Table 57. Merck Company Information
Table 58. Merck Introduction and Business Overview
Table 59. Merck Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Merck Targeted Drugs for Colorectal Cancer Product Offerings
Table 61. Merck Recent Development
Table 62. Amgen Company Information
Table 63. Amgen Introduction and Business Overview
Table 64. Amgen Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Amgen Targeted Drugs for Colorectal Cancer Product Offerings
Table 66. Amgen Recent Development
Table 67. F. Hoffmann-La Roche Ltd Company Information
Table 68. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 69. F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Product Offerings
Table 71. F. Hoffmann-La Roche Ltd Recent Development
Table 72. Novartis Company Information
Table 73. Novartis Introduction and Business Overview
Table 74. Novartis Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Novartis Targeted Drugs for Colorectal Cancer Product Offerings
Table 76. Novartis Recent Development
Table 77. Array BioPharma Company Information
Table 78. Array BioPharma Introduction and Business Overview
Table 79. Array BioPharma Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Array BioPharma Targeted Drugs for Colorectal Cancer Product Offerings
Table 81. Array BioPharma Recent Development
Table 82. Genentech Company Information
Table 83. Genentech Introduction and Business Overview
Table 84. Genentech Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Genentech Targeted Drugs for Colorectal Cancer Product Offerings
Table 86. Genentech Recent Development
Table 87. Bayer Company Information
Table 88. Bayer Introduction and Business Overview
Table 89. Bayer Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bayer Targeted Drugs for Colorectal Cancer Product Offerings
Table 91. Bayer Recent Development
Table 92. Sanofi Company Information
Table 93. Sanofi Introduction and Business Overview
Table 94. Sanofi Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Sanofi Targeted Drugs for Colorectal Cancer Product Offerings
Table 96. Sanofi Recent Development
Table 97. Lilly Company Information
Table 98. Lilly Introduction and Business Overview
Table 99. Lilly Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Lilly Targeted Drugs for Colorectal Cancer Product Offerings
Table 101. Lilly Recent Development
Table 102. Bristol myers squibb Company Information
Table 103. Bristol myers squibb Introduction and Business Overview
Table 104. Bristol myers squibb Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bristol myers squibb Targeted Drugs for Colorectal Cancer Product Offerings
Table 106. Bristol myers squibb Recent Development
Table 107. MSD lreland Company Information
Table 108. MSD lreland Introduction and Business Overview
Table 109. MSD lreland Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. MSD lreland Targeted Drugs for Colorectal Cancer Product Offerings
Table 111. MSD lreland Recent Development
Table 112. HUTCHMED Company Information
Table 113. HUTCHMED Introduction and Business Overview
Table 114. HUTCHMED Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. HUTCHMED Targeted Drugs for Colorectal Cancer Product Offerings
Table 116. HUTCHMED Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Targeted Drugs for Colorectal Cancer Downstream Customers
Table 120. Targeted Drugs for Colorectal Cancer Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Drugs for Colorectal Cancer Product Picture
Figure 2. Global Targeted Drugs for Colorectal Cancer Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Targeted Drugs for Colorectal Cancer Sales Volume (2019-2030) & (K Units)
Figure 5. Global Targeted Drugs for Colorectal Cancer Sales Price (2019-2030) & (US$/Unit)
Figure 6. Targeted Drugs for Colorectal Cancer Report Years Considered
Figure 7. Global Targeted Drugs for Colorectal Cancer Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Targeted Drugs for Colorectal Cancer Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Targeted Drugs for Colorectal Cancer Revenue in 2023
Figure 10. Targeted Drugs for Colorectal Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. EGFR Target Picture
Figure 12. BRAF Target Picture
Figure 13. MEK1/2 Targets Picture
Figure 14. BRAF V600 Target Picture
Figure 15. HER2 Target Picture
Figure 16. VEGFR-1/2/3 Targets Picture
Figure 17. PD-1 Target Picture
Figure 18. CTLA-4 Target Picture
Figure 19. Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Targeted Drugs for Colorectal Cancer Sales Value Market Share by Type, 2023 & 2030
Figure 21. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 22. Global Targeted Drugs for Colorectal Cancer Sales Volume Market Share by Type, 2023 & 2030
Figure 23. Global Targeted Drugs for Colorectal Cancer Price by Type (2019-2030) & (US$/Unit)
Figure 24. Product Picture of Hospital
Figure 25. Product Picture of Specialty Clinic
Figure 26. Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 27. Global Targeted Drugs for Colorectal Cancer Sales Value Market Share by Application, 2023 & 2030
Figure 28. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 29. Global Targeted Drugs for Colorectal Cancer Sales Volume Market Share by Application, 2023 & 2030
Figure 30. Global Targeted Drugs for Colorectal Cancer Price by Application (2019-2030) & (US$/Unit)
Figure 31. North America Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 32. North America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 33. Europe Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 34. Europe Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 35. Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 37. South America Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 38. South America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 39. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 41. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value (%), (2019-2030)
Figure 42. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume (%), (2019-2030)
Figure 43. United States Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 44. United States Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 45. United States Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 46. Europe Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 47. Europe Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 48. Europe Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 49. China Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 50. China Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 51. China Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 52. Japan Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 53. Japan Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 54. Japan Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 55. South Korea Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 56. South Korea Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 57. South Korea Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 58. Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 59. Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 60. Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 61. India Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 62. India Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 63. India Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 64. Targeted Drugs for Colorectal Cancer Industrial Chain
Figure 65. Targeted Drugs for Colorectal Cancer Manufacturing Cost Structure
Figure 66. Channels of Distribution (Direct Sales, and Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Targeted Drugs for Colorectal Cancer Market Trends
Table 2. Targeted Drugs for Colorectal Cancer Market Drivers & Opportunity
Table 3. Targeted Drugs for Colorectal Cancer Market Challenges
Table 4. Targeted Drugs for Colorectal Cancer Market Restraints
Table 5. Global Targeted Drugs for Colorectal Cancer Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Targeted Drugs for Colorectal Cancer Revenue Market Share by Company (2019-2024)
Table 7. Global Targeted Drugs for Colorectal Cancer Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Targeted Drugs for Colorectal Cancer Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Targeted Drugs for Colorectal Cancer Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Targeted Drugs for Colorectal Cancer Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Targeted Drugs for Colorectal Cancer Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Targeted Drugs for Colorectal Cancer
Table 13. Global Targeted Drugs for Colorectal Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Colorectal Cancer as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Targeted Drugs for Colorectal Cancer Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Targeted Drugs for Colorectal Cancer Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Targeted Drugs for Colorectal Cancer Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Targeted Drugs for Colorectal Cancer Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Targeted Drugs for Colorectal Cancer Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Targeted Drugs for Colorectal Cancer Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Targeted Drugs for Colorectal Cancer Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Targeted Drugs for Colorectal Cancer Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2019-2024) & (%)
Table 44. Global Targeted Drugs for Colorectal Cancer Sales Value by Region (2025-2030) & (%)
Table 45. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2019-2024) & (%)
Table 49. Global Targeted Drugs for Colorectal Cancer Sales Volume by Region (2025-2030) & (%)
Table 50. Global Targeted Drugs for Colorectal Cancer Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Targeted Drugs for Colorectal Cancer Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume, (2025-2030) & (K Units)
Table 57. Merck Company Information
Table 58. Merck Introduction and Business Overview
Table 59. Merck Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Merck Targeted Drugs for Colorectal Cancer Product Offerings
Table 61. Merck Recent Development
Table 62. Amgen Company Information
Table 63. Amgen Introduction and Business Overview
Table 64. Amgen Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Amgen Targeted Drugs for Colorectal Cancer Product Offerings
Table 66. Amgen Recent Development
Table 67. F. Hoffmann-La Roche Ltd Company Information
Table 68. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 69. F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. F. Hoffmann-La Roche Ltd Targeted Drugs for Colorectal Cancer Product Offerings
Table 71. F. Hoffmann-La Roche Ltd Recent Development
Table 72. Novartis Company Information
Table 73. Novartis Introduction and Business Overview
Table 74. Novartis Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Novartis Targeted Drugs for Colorectal Cancer Product Offerings
Table 76. Novartis Recent Development
Table 77. Array BioPharma Company Information
Table 78. Array BioPharma Introduction and Business Overview
Table 79. Array BioPharma Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Array BioPharma Targeted Drugs for Colorectal Cancer Product Offerings
Table 81. Array BioPharma Recent Development
Table 82. Genentech Company Information
Table 83. Genentech Introduction and Business Overview
Table 84. Genentech Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Genentech Targeted Drugs for Colorectal Cancer Product Offerings
Table 86. Genentech Recent Development
Table 87. Bayer Company Information
Table 88. Bayer Introduction and Business Overview
Table 89. Bayer Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bayer Targeted Drugs for Colorectal Cancer Product Offerings
Table 91. Bayer Recent Development
Table 92. Sanofi Company Information
Table 93. Sanofi Introduction and Business Overview
Table 94. Sanofi Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Sanofi Targeted Drugs for Colorectal Cancer Product Offerings
Table 96. Sanofi Recent Development
Table 97. Lilly Company Information
Table 98. Lilly Introduction and Business Overview
Table 99. Lilly Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Lilly Targeted Drugs for Colorectal Cancer Product Offerings
Table 101. Lilly Recent Development
Table 102. Bristol myers squibb Company Information
Table 103. Bristol myers squibb Introduction and Business Overview
Table 104. Bristol myers squibb Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bristol myers squibb Targeted Drugs for Colorectal Cancer Product Offerings
Table 106. Bristol myers squibb Recent Development
Table 107. MSD lreland Company Information
Table 108. MSD lreland Introduction and Business Overview
Table 109. MSD lreland Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. MSD lreland Targeted Drugs for Colorectal Cancer Product Offerings
Table 111. MSD lreland Recent Development
Table 112. HUTCHMED Company Information
Table 113. HUTCHMED Introduction and Business Overview
Table 114. HUTCHMED Targeted Drugs for Colorectal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. HUTCHMED Targeted Drugs for Colorectal Cancer Product Offerings
Table 116. HUTCHMED Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Targeted Drugs for Colorectal Cancer Downstream Customers
Table 120. Targeted Drugs for Colorectal Cancer Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Drugs for Colorectal Cancer Product Picture
Figure 2. Global Targeted Drugs for Colorectal Cancer Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Targeted Drugs for Colorectal Cancer Sales Volume (2019-2030) & (K Units)
Figure 5. Global Targeted Drugs for Colorectal Cancer Sales Price (2019-2030) & (US$/Unit)
Figure 6. Targeted Drugs for Colorectal Cancer Report Years Considered
Figure 7. Global Targeted Drugs for Colorectal Cancer Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Targeted Drugs for Colorectal Cancer Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Targeted Drugs for Colorectal Cancer Revenue in 2023
Figure 10. Targeted Drugs for Colorectal Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. EGFR Target Picture
Figure 12. BRAF Target Picture
Figure 13. MEK1/2 Targets Picture
Figure 14. BRAF V600 Target Picture
Figure 15. HER2 Target Picture
Figure 16. VEGFR-1/2/3 Targets Picture
Figure 17. PD-1 Target Picture
Figure 18. CTLA-4 Target Picture
Figure 19. Global Targeted Drugs for Colorectal Cancer Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Targeted Drugs for Colorectal Cancer Sales Value Market Share by Type, 2023 & 2030
Figure 21. Global Targeted Drugs for Colorectal Cancer Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 22. Global Targeted Drugs for Colorectal Cancer Sales Volume Market Share by Type, 2023 & 2030
Figure 23. Global Targeted Drugs for Colorectal Cancer Price by Type (2019-2030) & (US$/Unit)
Figure 24. Product Picture of Hospital
Figure 25. Product Picture of Specialty Clinic
Figure 26. Global Targeted Drugs for Colorectal Cancer Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 27. Global Targeted Drugs for Colorectal Cancer Sales Value Market Share by Application, 2023 & 2030
Figure 28. Global Targeted Drugs for Colorectal Cancer Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 29. Global Targeted Drugs for Colorectal Cancer Sales Volume Market Share by Application, 2023 & 2030
Figure 30. Global Targeted Drugs for Colorectal Cancer Price by Application (2019-2030) & (US$/Unit)
Figure 31. North America Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 32. North America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 33. Europe Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 34. Europe Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 35. Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 37. South America Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 38. South America Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 39. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Targeted Drugs for Colorectal Cancer Sales Value by Country (%), 2023 VS 2030
Figure 41. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Value (%), (2019-2030)
Figure 42. Key Countries/Regions Targeted Drugs for Colorectal Cancer Sales Volume (%), (2019-2030)
Figure 43. United States Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 44. United States Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 45. United States Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 46. Europe Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 47. Europe Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 48. Europe Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 49. China Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 50. China Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 51. China Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 52. Japan Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 53. Japan Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 54. Japan Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 55. South Korea Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 56. South Korea Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 57. South Korea Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 58. Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 59. Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 60. Southeast Asia Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 61. India Targeted Drugs for Colorectal Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 62. India Targeted Drugs for Colorectal Cancer Sales Value by Type (%), 2023 VS 2030
Figure 63. India Targeted Drugs for Colorectal Cancer Sales Value by Application (%), 2023 VS 2030
Figure 64. Targeted Drugs for Colorectal Cancer Industrial Chain
Figure 65. Targeted Drugs for Colorectal Cancer Manufacturing Cost Structure
Figure 66. Channels of Distribution (Direct Sales, and Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Digital Multifunction Meter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
Whole Current Energy Meter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
High Current Air Circuit Breaker - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232